PCSK9 inhibitors for treatment of high cholesterol: effectiveness, value, and value-based price benchmarks : final report

PCSK9 inhibitors for treatment of high cholesterol: effectiveness, value, and value-based price benchmarks : final report

Collection:
Health Policy and Services Research
Author(s):
Tice, Jeffrey A., author
Ollendorf, Daniel A., author
Cunningham, Courtney, author
Pearson, Steven D., author
Kazi, Dhruv S., author
Coxson, Pamela G., author
Moran, Andrew E., author
Penko, Joanne, author
Guzman, David, author
Bibbins, Kirsten, author
Contributor(s):
Institute for Clinical and Economic Review, issuing body.
New England Comparative Effectiveness Public Advisory Council, issuing body.
Publication:
[Boston, MA] : Institute for Clinical and Economic Review, November 24, 2015
Language(s):
English
Format:
Text
Subject(s):
Anticholesteremic Agents -- therapeutic use
Azetidines -- therapeutic use
Enzyme Inhibitors -- therapeutic use
Hypercholesterolemia -- therapy
Hyperlipoproteinemia Type II -- prevention & control
Proprotein Convertases -- economics
Serine Endopeptidases -- economics
New England
United States
Genre(s):
Technical Report
Abstract:
Background. The goal of this report is to address the key issues that patients, providers, and payers face when making decisions about PCSK9 inhibitor therapy and to support the dialogue needed for successful action to improve the quality and value of health care for all patients. The scope for this assessment utilizes the PICOTS (Population, Intervention, Comparators, Outcomes, Timing, and Settings) framework. The evidence review is based on 25 clinical trials and two published systematic reviews and meta-analyses. The results were cross-checked with the manufacturers' FDA submission documents and the FDA's briefing documents. Topic in Context. In summarizing the contextual considerations for appraisal of a health care intervention, we seek to highlight the four following specific issues: (1) Is there a particularly high burden/severity of illness? (2) Do other acceptable treatments exist? (3) Are other, equally or more effective treatments nearing introduction into practice? (4) Would other societal values accord substantially more or less priority to providing access to this treatment for this patient population?
Copyright:
Reproduced with permission of the copyright holder. Further use of the material is subject to CC BY license. (More information)
Extent:
1 online resource (1 PDF file (i-v, ES 1-ES 18, 115 pages))
Illustrations:
Illustrations
NLM Unique ID:
101672684 (See catalog record)
Permanent Link:
http://resource.nlm.nih.gov/101672684